ENTA vs PRTA

For growth investors, Enanta Pharmaceuticals, Inc.

(ENTA) is the stronger pick with -3. 4% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Enanta Pharmaceuticals, Inc. (ENTA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -52.

7%, compared to -70. 1% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: ENTA returned -39. 0% versus PRTA's -70. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Enanta Pharmaceuticals, Inc. 's 1. 44β — meaning ENTA is approximately 50% more volatile than PRTA relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Enanta Pharmaceuticals, Inc.

(ENTA) is pulling ahead at -3. 4% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Enanta Pharmaceuticals, Inc. grew EPS 29. 9% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, ENTA leads at -8. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Enanta Pharmaceuticals, Inc.

(ENTA) is the more profitable company, earning -125. 4% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -125. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENTA leads at -130. 7% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ENTA: 216.

3% to $48. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Both have compounded well over 10 years (PRTA: -70. 8%, ENTA: -39. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.